Market: NASD |
Currency: USD
Address: One Kendall Square
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
📈 CAMP Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$15.25
-
Upside/Downside from Analyst Target:
859.12%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
0-10%
-
Net Income Growth Range (1Y):
0-10%
-
Revenue Growth Range (1Y):
50-100%
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for CAMP
| Date | Reported EPS |
|---|
| 2025-08-14 | -0.62 |
| 2025-08-12 | - |
| 2025-05-13 | -0.62 |
| 2024-11-21 | -24.19 |
📰 Related News & Research
🔍 View more Reports
